← Back to Program
Evolution
H3

Regulatory Pathway as Capital Structure

How FDA Classification Determines Your Cap Table

Not regulatory training — structural consequence analysis. How 510(k) vs. PMA vs. IND-to-NDA pathways determine capital requirements, funding round count, dilution trajectory, and founder equity at exit. How acquirers price regulatory risk into deal terms.

Coming Soon

This evolution is under development. Content will be available when the next cohort begins.

Contact Us
Next cohort begins soon
Next Cohort begins June 17, 2026